Conflict of Interest (COI)

Significant Financial Interest is defined as a Financial Interest consisting of one or more of the following interests of the Investigator or the Investigator's Covered Family Members that reasonably appears to be related to the Investigator's Institutional Responsibilities:

Remuneration or Equity Interest in a Publicly Traded Entity: A Financial Interest in which the value of any Remuneration received from the entity in the twelve months preceding the disclosure and the value of any Equity Interest in the entity as of the date of disclosure, when aggregated, exceeds $5,000;

Remuneration or Equity Interest in a Non-Publicly Traded Entity: A Financial Interest in which the value of any Remuneration received from the entity in the twelve months preceding the disclosure, when aggregated, exceeds $5,000, or when the Investigator holds any Equity Interest;

Intellectual Property: Any receipt of income for Intellectual property rights and interests (e.g. patents, copyrights);

Reimbursed or Sponsored Travel: Any reimbursed or sponsored travel in the twelve months preceding the disclosure in which the value (aggregated per entity that reimburses or sponsors the travel) exceeds $5,000. This does not apply to Investigators who do not receive PHS funding; See "SFI Exclusions" below for additional exclusions for travel that is not reportable.

SFI Exclusions: The term Significant Financial Interest (SFI) does not include the following types of financial interests:

1. Salary, royalties, or other Remuneration paid by UNT to the Investigator or Covered Family Member if the Investigator or Covered Family Member is currently employed or otherwise appointed by UNT, including Intellectual Property rights assigned to UNT and agreements to share in royalties related to such rights;
2. Income from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator or Covered Family Member does not directly control the investment decisions made in these vehicles;
3. Income from seminars, lectures, or teaching engagements sponsored by a federal, state, or local government agency, an institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a Research institute that is affiliated with an institution of higher education;
4. Income from service on advisory committees or review panels for a federal, state, or local government agency, an institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a Research institute that is affiliated with an institution of higher education;
5. Travel that is reimbursed or sponsored by a federal, state, or local government agency, an institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a Research institute that is affiliated with an institution of higher education; and
6. Travel not meeting the exceptions in part (5) above, but is valued at less than $5,000 per entity that reimburses or sponsors the travel.

Marco Buongiorno Nardelli, Ph.D.

Regents Professor, Physics and Joint Appt to the Division of Composition Studies

Elias Mpofu, Ph.D.

Professor, Rehabilitation and Health Services

Victor Prybutok, Ph.D.

Chair, COI Committee

Vice Provost, Toulouse Graduate School, Regents Professor of Decision Sciences

Brian Sauser, Ph.D.

Professor, Marketing, Logistics, & Operations Management

Youngwook Won, Ph.D.

Associate Professor, Biomedical Engineering

UNT's COI Policy

2011 PHS Conflict of Interest Regulations, 42 CFR Part 50, Subpart F

NIH Conflict of Interest Page

NIH FAQs

Summary of Major Changes from 1995 to 2011 COI Regulations

Journal Disclosure Templates